^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DLK1 expression

    i
    Other names: DLK1, Delta Like Non-Canonical Notch Ligand 1, PG2, Pref-1, Delta1, FA1, ZOG, Protein Delta Homolog 1, DLK-1, DLK, Delta-Like 1 Homolog (Drosophila), Delta-Like Homolog (Drosophila), Preadipocyte Factor 1, Delta-Like 1 Homolog, Fetal Antigen 1, Secredeltin, PREF1
    Entrez ID:
    8788
    19d
    A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. (PubMed, Cancer Cell)
    ADCT-701, a DLK1-targeting antibody-drug conjugate (ADC), shows potent and specific cytotoxicity in DLK1-expressing neuroblastoma xenograft models. Since high DLK1 expression is found in several adult and pediatric cancers, our study demonstrates the utility of a proteogenomic approach and credentials DLK1 as an immunotherapeutic target.
    Journal • IO biomarker
    |
    DLK1 (Delta Like Non-Canonical Notch Ligand 1)
    |
    DLK1 expression
    |
    ADCT-701
    2ms
    Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma. (PubMed, bioRxiv)
    This study presents DLK1 as a novel biomarker in ACC with opportunities for use in the diagnosis, prognosis and longitudinal follow up of patients. DLK1, a marker of adrenocortical stem cells, is re-expressed in ACC, is measurable in patients' serum and is associated with increased malignancy.
    Journal
    |
    DLK1 (Delta Like Non-Canonical Notch Ligand 1)
    |
    DLK1 expression
    1year
    Targeting the pericyte antigen DLK1 with an alpha type-1 polarized dendritic cell vaccine results in tumor vascular modulation and protection against colon cancer progression. (PubMed, Front Immunol)
    Our pre-clinical data demonstrate the αDC1 vaccine's ability to induce anti-tumor effects by facilitating cytotoxic T lymphocyte activity and ablating the tumor vasculature. This work, overall, provides a foundation to further interrogate immune-mediated mechanisms of protection in order to help devise efficacious αDC1-based strategies for patients with CRC.
    Journal
    |
    DLK1 (Delta Like Non-Canonical Notch Ligand 1)
    |
    DLK1 expression
    |
    aDC1 vaccine